v3.26.3
SEGMENT INFORMATION
 9 Months Ended
Sep. 30, 2026
Segment Reporting [Abstract]  
SEGMENT INFORMATION SEGMENT INFORMATION
Reportable Segments
The Company’s interim Chief Executive Officer (“CEO”), who is the Company’s Chief Operating Decision Maker, manages the business through three operating segments, consistent with how the Company’s interim CEO: (i) assesses operating performance on a regular basis, (ii) makes resource allocation decisions and (iii) designates responsibilities of his direct reports. The Company operates in the following operating segments, which also qualify as reportable segments: (i) Vision Care, (ii) Pharmaceuticals and (iii) Surgical. These segments are generally determined based on the decision-making structure of Bausch + Lomb and the grouping of similar products and services.
•The Vision Care segment consists of: (i) sales of contact lenses that span the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses, and (ii) sales of contact lens care products, OTC eye drops that address various conditions, including eye allergies, conjunctivitis, dry eye and redness relief, and eye vitamin and mineral supplements.
•The Pharmaceuticals segment consists of sales of a broad line of proprietary and generic pharmaceutical products for post-operative treatments and the treatment of a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases.
•The Surgical segment consists of sales of medical device equipment, consumables and technologies for the treatment of cataracts, corneal, vitreous, retinal and refractive eye conditions, which includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for ophthalmic surgery.
The Company’s Chief Operating Decision Maker uses segment profit to assess operating performance and make resource allocation decisions for each of its segments. Segment profit is based on operating income after the elimination of intercompany transactions. Certain costs, such as Amortization of intangible assets, and Other expense, net, are not included in the measure of segment profit, as management excludes these items in assessing segment financial performance.
Corporate includes the finance, treasury, certain research and development programs, tax and legal operations of Bausch + Lomb’s businesses and incurs certain expenses, gains and losses related to the overall management of Bausch + Lomb, which are not allocated to the other business segments. In assessing segment performance and managing operations, management does not review segment assets. Furthermore, a portion of share-based compensation is considered a corporate cost, since the amount of such expense depends on company-wide performance rather than the operating performance of any single segment.





Segment Revenues and Profit
Segment revenues and profits for the three and nine months ended September 30, 2026 and 2025 were as follows:
Vision CarePharmaceuticalsSurgicalTotal
Three Months Ended September 30,
(in millions)20262025202620252026202520262025
Revenues
Product Sales$773 $734 $366 $329 $232 $214 $1,371 $1,277 
Other Revenues1 2 1 1 2 1 4 4 
774 736 367 330 234 215 1,375 1,281 
Expenses
Cost of goods sold (excluding amortization and impairments of intangible assets)281 279 88 106 116 124 
Cost of other revenues— — 1 1 — — 
Selling, general and administrative240 225 127 132 77 72 
Research and development9 15 17 15 9 11 
Segment Profit$244 $217 $134 $76 $32 $8 410 301 
Corporate(168)(153)
Amortization of intangible assets(57)(68)
Other (expense) income, net(30)15 
Operating income155 95 
Interest income2 3 
Interest expense(95)(101)
Loss on extinguishment of debt— 3 
Foreign exchange and other (4)(3)
Income (loss) before provision for income taxes$58 $(3)
Vision CarePharmaceuticalsSurgicalTotal
Nine Months Ended September 30,
(in millions)20262025202620252026202520262025
Revenues
Product Sales$2,262 $2,139 $1,024 $902 $713 $641 $3,999 $3,682 
Other Revenues7 6 2 4 5 4 14 14 
2,269 2,145 1,026 906 718 645 4,013 3,696 
Expenses
Cost of goods sold (excluding amortization and impairments of intangible assets)843 820 255 303 396 390 
Cost of other revenues— — 2 4 — — 
Selling, general and administrative715 689 414 439 230 218 
Research and development36 34 66 36 34 34 
Segment Profit$675 $602 $289 $124 $58 $3 1,022 729 
Corporate(499)(497)
Amortization of intangible assets(171)(202)
Other expense, net(81)(29)
Operating income271 1 
Interest income10 9 
Interest expense(285)(323)
Loss on extinguishment of debt(1)(6)
Foreign exchange and other (12)(11)
Loss before provision for income taxes$(17)$(330)
Revenues by Segment and by Product Category
Revenues by segment and product category were as follows:
Vision CarePharmaceuticalsSurgicalTotal
Three Months Ended September 30,
(in millions)20262025202620252026202520262025
Pharmaceuticals$1 $1 $318 $279 $— $— $319 $280 
Devices285 270 — — 232 214 517 484 
OTC477 454 — — — — 477 454 
Branded and Other Generics10 9 48 50 — — 58 59 
Other revenues1 2 1 1 2 1 4 4 
$774 $736 $367 $330 $234 $215 $1,375 $1,281 
Nine Months Ended September 30,
20262025202620252026202520262025
Pharmaceuticals$3 $3 $882 $759 $— $— $885 $762 
Devices808 763 — — 713 641 1,521 1,404 
OTC1,418 1,344 — — — — 1,418 1,344 
Branded and Other Generics33 29 142 143 — — 175 172 
Other revenues7 6 2 4 5 4 14 14 
$2,269 $2,145 $1,026 $906 $718 $645 $4,013 $3,696 
The top ten products/franchises represented 57% and 55% of total revenues for the nine months ended September 30, 2026 and 2025, respectively.